Australia: Federal Court considers the new patent entitlement provisions for the first time

In a recent interlocutory injunction proceeding before his Honour Justice Rares in the Federal Court of Australia,1 the new patent entitlement provisions of the Patents Act 1990 (Cth), which were introduced on 15 April 2013, were considered, it is understood, for the first time.

The amendments provide that a patent is not invalid merely because it was granted to a person who is not entitled to it, and also require that the Court must not make an order revoking a patent unless it is satisfied that, in all the circumstances, it would be just and equitable to do so. Depending on the interpretation of these provisions, allegations of lack of entitlement may be less often used in future patent invalidity cases.

In the proceeding before Justice Rares, Reckitt Benckiser Healthcare (UK) Limited and Reckitt Benckiser (Australia) Pty Limited sought to restrain GlaxoSmithKline Australia Limited from infringing Reckitt Benckiser's Patent relating to a liquid dispensing apparatus, comprising a bottle, a flat nosed syringe, and a bottle neck liner in which the syringe is inserted to allow take up of the liquid when the bottle is inverted.2 GSK brought a cross-claim against Reckitt Benckiser challenging the validity of Reckitt Benckiser's Patent on various bases including lack entitlement.


The Patent was filed in 2003, and named as inventors two employees of Boots Healthcare International, which was subsequently acquired by the Reckitt Benckiser group of companies.

Contrary to what the register shows, GSK alleged that three employees or officers of the company that originally manufactured and supplied the liquid dispensing apparatus to Boots, Hubert De Backer NV, were the true inventors and that Reckitt Benckiser was therefore not entitled to the Patent.


Section 15 of the Patents provides that a patent may only be granted to:

  1. the inventor;
  2. a person who, on the grant of the patent, would be entitled to have the patent assigned to them;
  3. a person who derives title from the inventor or entitled person; or
  4. the legal representative of a deceased entitled person.

Further, section 138(3) of the Patents Act provides that the court may revoke the patent, wholly or so far as it relates to a claim, if the patentee is not entitled to the patent.

The correct application of the provisions has been the subject of debate.


For example, in University of Western Australia v Gray,3 the University of Western Australia claimed that inventions developed by Dr Gray during his course of employment at UWA belonged to UWA due to an implied term of Dr Gray's contract with UWA. The Court found that Dr Gray, despite being employed by UWA, was entitled to the patent. This decision was the subject of a 400 page judgment by Justice French at first instance, a 100 page judgment by the Full Court, and an application for special leave to the High Court (which was refused).

In University Of British Columbia v Conor Medsystems Inc,4 Conor alleged that patents granted jointly to UBC and Angiotech (the second appellant) should be revoked if it could be shown that UBC and Angiotech's claim to entitlement stemmed from some, but not all of the actual inventors of the invention. At first instance Finkelstein J found that UBC was not entitled to the patent and the patent should be revoked. UBC then appealed to the Full Federal Court which set aside Finkelstein J's orders but ordered that the matter be remitted back to Finkelstein J as there was insufficient evidence before the Full Federal Court to answer the preliminary question of whether the alleged facts support revocation of the patent. The Full Federal Court suggested that UBC may be able to establish some act or conduct whereby it could demonstrate entitlement. The matter was later settled.

In Davies Shephard Pty Ltd v Stack,5 Davies alleged that Stack was not entitled to a patent developed by Stack and Grieves as the application was filed in the name of Stack alone. The Court ultimately found that Stack was not entitled to the patent as no relationship existed between Stack and Grieves whereby Stack alone was entitled to the patent. The Full Court came to this conclusion despite Stack leading evidence that Stack and Grieves intended to assign the patent to a company jointly owned and controlled by them.


Legislators have recognised the complications arising from the provisions and have stated:

Patent ownership issues can be complicated, and it can be unclear, even to the parties involved, who has entitlement to particular patent claims.6 ...
It is often difficult to determine the persons correctly entitled to the patent and errors in entitlement are often no more than an honest mistake by the inventors and applicants. Revocation of the patent is often an unnecessarily harsh outcome.7

In light of these complexities, on 15 April 2013, as part of amendments under the Intellectual Property Laws Amendment (Raising the Bar) Act 2012 (Cth), a new section 138(4) was added to the Patents Act. Section 138(4) provides that:

(4) A court must not make an order under subsection (3) on the ground that the patentee is not entitled to the patent unless the court is satisfied that, in all the circumstances, it is just and equitable to do so.

Additionally, a new section 22A was added to the Patents Act and provides that:

A patent is not invalid merely because:

  1. the patent, or a share in the patent, was granted to a person who was not entitled to it; or
  2. the patent, or a share in the patent, was not granted to a person who was entitled to it.


While GSK alleged that Reckitt Benckiser was not entitled to the Patent in suit, Justice Rares was provided with an agreement entered into by Boots and HDB in 2006. The recitals to this agreement, together with evidence lead by Reckitt Benckiser at the interlocutory hearing, demonstrated that, at least for interlocutory purposes, Boots had initiated a project in the late 1990s to develop a liquid dispensing apparatus to be used with Nurofen for Children, specifically a dosing system that used a flat nosed syringe and bottle neck insert combination, as research conducted by Boots had indicated that children associated traditional syringes with injections.

As part of the project, Boots had identified HDB as a potential supplier of the dispensing apparatus, as it had experience with similar products. Boots determined that the existing HDB bottle inserts were not suitable for use with the Nurofen for Children product, and proposed various modifications to the design, over a period of approximately 24 months. After the design of the modified dosing system had been finalised, Boots applied for a patent in relation to the invention, and in accordance with the Agreement, Boots amended the Patent claims so as to capture only the specific inventions made by the Boots employees who were the named inventors of the Patent.

In the Agreement, HDB explicitly acknowledged that Boots was the owner of the invention the subject of the Patent on the basis that Boots (by its employees) had created the invention. HDB also acknowledged that it would not contest the ownership, validity, inventorship or any other issues relating to the Patent.

In addition to the Agreement, evidence was lead that the named inventors had signed declarations that they were the original, first and joint inventors of the subject matter claimed in the relevant PCT application number, from which the Patent was derived, as well as "Inventor's Acknowledgment" documents acknowledging Boots' rights in the invention.


After agreeing with counsel for both parties that sections 22A and 138(4) of the Patents Act applied in these proceedings, 8 Justice Rares considered the application of the two sections to the facts. In doing so, his Honour referred to the Agreement, noting that HDB and Reckitt Benckiser made their intentions in relation to the Patent very clear.

Relevantly, his Honour stated that:

Even if Glaxo were able to establish, as I do not think it has at a prima facie level, that there was a sufficient doubt as to the assertions made by Ms Dallison and Mr Harrison that they were the inventors, s 22A of the Act provides that a patent is not invalid merely because it was granted to a person who was not entitled to it. Moreover, s 138(4) of the Act provides that the Court cannot make an order that a patent be revoked on the ground that patentee is not entitled to it unless the Court is satisfied in all the circumstances that it is just and equitable to do so. That requirement must be construed in the context of the circumstances here. 9

After referring to the Agreement, his Honour noted that HDB effectively treated Boots as entitled to the Patent:

In my opinion, the likelihood is that if the matter of entitlement were tried on the present material, the Court would be very likely to find that HDB had effectively treated Boots as either the person entitled to the benefit of the invention, or an assignee of it, even though the Boots agreement itself is not a formal assignment.10

It was also relevant that GSK was not a party to the Agreement:

There can be little doubt, on the present evidence, that justice and equity would regard the position that the two parties with an interest in the invention had arrived at in their agreement in 2006 should not be disturbed at the suit of a third party (Glaxo). Glaxo's only interest is to displace the property right that, if nothing else, the Boots agreement appears to have conferred on Boots and now Reckitt, as its assignee.11

In rejecting GSK's entitlement case on an interim basis and finding it unjust and unconscionable to ignore the agreement between the two parties,12 his Honour further said that one must have regard to public interest when considering sections 22A and 138(4):

But if this was patentable – and assuming it is because the entitlement issue is just about who is entitled to assert the right – I mean, you're basically saying what is effectively under a different guise an assignment should be ignored. And that strikes me as being something with the Act as now amended doesn't really suggest would be in the public interest to allow that to be litigated and run and succeed.13


Although Justice Rares' findings are only interlocutory, the extent to which his Honour took into account the recently amended entitlement provisions is interesting.


1Reckitt Benckiser Healthcare (UK) Ltd v GlaxoSmithKline Australia Pty Ltd [2013] FCA 583.

2Australian Patent number 2003283537 entitled "Improvements in and relating to liquid dispensing".

3See University of Western Australia v Gray (No 20) [2008] FCA 498, University of Western Australia v Gray [2009] FCAFC 116 and University of Western Australia v Gray [2010] HCATrans 11.

4See Conor Medsystems Inc v University of British Columbia (No 2) [2006] FCA 32 and University Of British Columbia And Another V Conor Medsystems Inc. [2006] FCAFC 154.

5See Stack v Davies Shephard Pty Ltd [2001] FCA 501.

6Intellectual Property Laws Amendment (Raising the Bar) Bill 2011 (Cth) Explanatory Memorandum at item 31.

7Intellectual Property Laws Amendment (Raising the Bar) Bill 2011 (Cth) Explanatory Memorandum at item 75.

8See the transition provisions in section 2 of the Intellectual Property Laws Amendment (Raising the Bar) Act 2012 (Cth).

9Reckitt Benckiser Healthcare (UK) Ltd v GlaxoSmithKline Australia Pty Ltd [2013] FCA 583 at [53].

10Reckitt Benckiser Healthcare (UK) Ltd v GlaxoSmithKline Australia Pty Ltd [2013] FCA 583 at [54].

11Reckitt Benckiser Healthcare (UK) Ltd v GlaxoSmithKline Australia Pty Ltd [2013] FCA 583 at [55].

12Transcript for Reckitt Benckiser Healthcare (UK) Ltd v GlaxoSmithKline Australia Pty Ltd, 28 May 2013, page 123 lines 31-34.

13Transcript for Reckitt Benckiser Healthcare (UK) Ltd v GlaxoSmithKline Australia Pty Ltd, 28 May 2013, page 120 lines 6-11.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Most awarded firm and Australian deal of the year
Australasian Legal Business Awards
Employer of Choice for Women
Equal Opportunity for Women
in the Workplace (EOWA)

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Mondaq Advice Centre (MACs)
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.